News

Yahoo Finance6mon
TORL BioTherapeutics Announces Appointment of Aran Maree, M.D., as Chief Medical Officer and Initiates TORL-1-23 Registration-Enabling Phase 2 Study in Platinum-Resistant ...
Alles, Chairman and Chief Executive Officer of TORL Biotherapeutics. "Aran Maree is among the most accomplished and experienced physician-leaders in the biopharmaceutical industry, and TORL will ...
pharmaphorum4d
TORL rakes in $158m for ADCs, and other bio financings
Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics. Antibody-drug conjugate specialist TORL ...
Yahoo Finance8mon
TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress
TORL-1-23 Demonstrates Clinically Meaningful, Durable and Confirmed Responses with a Generally Manageable Safety Profile in Patients with Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian ...
WREG8mon
TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress
TORL BioTherapeutics, LLC (TORL Bio) is a clinical-stage biopharmaceutical company developing new antibodies, both monoclonal (mAbs) and drug conjugates (ADCs), with the goal of transforming the ...
The Victoria Advocate6mon
TORL BioTherapeutics Announces Appointment of Aran Maree, M.D., as Chief Medical Officer and Initiates TORL-1-23 Registration-Enabling Phase 2 Study in Platinum-Resistant ...
You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...